KUALA LUMPUR, Oct 26 (Bernama) — Malaysia made history this month when one of its Medical Oncologist, Dr Voon Pei Jye from Sarawak General Hospital (SGH) became the first Malaysian to be invited to co-author a First-in-Human trial publication. The results of the clinical trial was presented as a late-breaking oral presentation at the AACR-NCI-EORTC International Conference 2023 in Boston. Dr Voon’s significant contribution to the First-in-Human trial led to him being named as co-author in this distinguished platform. The said trial that was recently initiated in SGH in June this year, also places SGH and Dr Voon alongside top-ranking cancer institutes globally, and this include the highly renowned Memorial Sloan Kettering Cancer Center (2nd in global ranking) and the Dana-Faber Cancer Institute (8th in global ranking) both located in the United States.
Dr Voon was also recognized as the Regional First Recruiter for this First-in-Human clinical trial that aims to assess the preliminary safety and anti-tumor activity of an investigational product, which is a first-in-class, KRASG12C inhibitor in patients with advanced solid tumors with KRASG12C mutations. Dr Voon attributed his success to his dedicated team of Study Coordinators, Erfan and Li Fang, as well as the Clinical Research Centre (CRC) team at SGH as they have been instrumental to the delivery of the clinical trial.
